

**DOCKET NO.: TJU-2510**

**PATENT**



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**In Re Application of:**

**Carlo M. Croce**

**Application No.: 09/357,675**

**Filing Date: July 20, 1999**

**For: NITRILASE HOMOLOGS**

**Confirmation No.: 9577**

**Group Art Unit: 1632**

**Examiner: Scott David Priebe**

**RECEIVED**  
JAN 20 2004  
TECH CENTER 1600/2900

**EXPRESS MAIL LABEL NO: EV 160092130 US**  
**DATE OF DEPOSIT: January 12, 2004**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

### **INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached;

or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith
- ☐ Copies of references listed on the attached Form PTO 1449 are not required to be submitted pursuant to the June 30, 2003 recent revisions to 37 CFR § 1.98(a)(2)(i).


## EXCEPT THAT:

- ☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- ☐ In accordance with § 1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. § 120 have been made in the instant application:
- ☐ Copies of references [list as appropriate] listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior Application No. \_\_\_\_\_, filed \_\_\_\_\_.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

- ☐ The relevance of those listed references which are not in the English language is as follows:
- ☒ There are no listed references which are not in the English language.

Date: January 12, 2004

  
Tara L. Rachinsky  
Registration No. 47,875

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. TJU-2510	Application No. 09/357,675
	Applicant Carlo M. Croce	
	Filing Date July 20, 1999	Group 1632
	Confirmation No. 9577	

**RECEIVED**  
JAN 20 2004  
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
1	Accession No. U46922, <i>PubMed</i> – <i>Nucleotide</i> , May 8, 1996, <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a> , 2 pages	
2	Accession No. AF047699 <i>PubMed</i> – <i>Nucleotide</i> , July 16, 2001, <a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a> , 2 pages	
3	Huillebrand, H., et al., "Structure of the gene encoding nitrilase 1 from <i>Arabidopsis thaliana</i> ," <i>Gene</i> , 1996, 170, 197-200	
4	Ohta, M., et al., "The <i>FHIT</i> gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers," <i>Cell</i> , February 23, 1996, 84, 587-597	
5	Siprashvili, Z., et al., "Replacement of <i>Fhit</i> in cancer cells suppresses tumorigenicity," <i>Proc. Natl. Acad. Sci. USA</i> , December 1997, 94, 13771-13776	
6	Sozzi, G., et al., "The <i>FHIT</i> gene at 3p14.2 is abnormal in lung cancer," <i>Cell</i> , April 5, 1996, 85, 17-26	
7	Sozzi, G., et al., "Loss of <i>FHIT</i> function in lung cancer and preinvasive bronchial lesions," <i>Cancer Res.</i> , November 15, 1998, 58, 5032-5037	

EXAMINER	DATE CONSIDERED
----------	-----------------